Ulcerative colitis drug study cut short, but data still valuable
NCT ID NCT05069259
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This study aimed to see how well the drug tofacitinib works for people with moderate to severe ulcerative colitis in everyday medical practice in Switzerland. It included 18 adults who were already prescribed the drug. The study was stopped early, but researchers still collected information on symptoms and gut inflammation to understand how patients respond to treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Fribourgeois de Gastroenterologie
Fribourg, Switzerland
-
Clarunis, Universitätsspital
Basel, Switzerland
-
Kantonsspital Baselland
Liestal, Switzerland
-
Kantonsspital St, Gallen
Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
-
Verein IBD Study Group
Bern, CH - 3012, Switzerland
Conditions
Explore the condition pages connected to this study.